

Malawi

Support for Vaccine: Rotavirus This Decision Letter sets out the Programme Terms of a Programme.

Country:	Malawi				The second	Orgalis (1)	Louis Ind.	
Vaccine grant number: 1214-MWI-13B-X, 1516-MWI-13b-X, 1720-MWI-13b-X								
Date of Decision Letter: 10 September 2019								
Date of the Partnership Framework A			reement:	29	October 20	13		
Programme title: New Vaccine			Support (NVS),	Rotavirus, Ro	outine			
Vaccine type:		Rotavirus						
Requested product presentation and formulation of vaccine:								
RV1, 1 dose/	plastic tube, li	9						
Programme	Duration:1	2012-2020	2			a. 115.2 Sp	C relicione	
. Programme Budget (indicative): ² (subject to the terms of the Partnership Framework Agreement, if applicable)							reement, if	
	2012-2018	2019	2020	2021	2022	2023	Total ²	
Programme Budget (US\$)	17,349,048	3,415,500	3,199,500	_	70. 20 20.		23,964,048	
			6611,500 was dis	sbursed on 30	0/01/2012 and	d 27/08/2012	2	
Product swi								
	tch grant	Not applicable	е					
Indicative A			e (subject to the te applicable)	erms of the P	Partnership Fr	ramework Aç	greement, if	
Type of s	nnual Amount upplies to be sed with Gavi	ts:³	(subject to the to applicable)	erms of the P		ramework Aç	greement, if	
Type of s	nnual Amoun	ts:³	(subject to the te	erms of the P	Partnership Fr 2019	amework Aç	greement, if	
Type of s	nnual Amount upplies to be sed with Gavi	ts:³	(subject to the to applicable)	erms of the P		amework Aડ્	greement, if	
	Vaccine gran Date of Decis Date of the F Programme Vaccine type Requested p RV1, 1 dose/ Programme Programme Programme US\$ Vaccine intro	Vaccine grant number: Date of Decision Letter: Date of the Partnership Fr Programme title: Vaccine type: Requested product prese RV1, 1 dose/plastic tube, lic Programme Duration: Programme Budget (indices) 2012-2018 Programme Budget (US\$) 17,349,048 Vaccine introduction grant	Vaccine grant number: Date of Decision Letter: Date of the Partnership Framework Age Programme title: New Vaccine Vaccine type: Rotavirus Requested product presentation and for RV1, 1 dose/plastic tube, liq Programme Duration: 2012-2020 Programme Budget (indicative): 2 2012-2018 2019 Programme Budget (US\$) 17,349,048 3,415,500 Vaccine introduction grant	Vaccine grant number: 1214-MWI-13B- Date of Decision Letter: 10 September 2 Date of the Partnership Framework Agreement: Programme title: New Vaccine Support (NVS), Vaccine type: Rotavirus Requested product presentation and formulation of various (SV1, 1 dose/plastic tube, liq Programme Duration: 2012-2020 Programme Budget (indicative): (subject to the teapplicable) 2012-2018 2019 2020 Programme Budget (US\$) 17,349,048 3,415,500 3,199,500 Vaccine introduction grant	Vaccine grant number: 1214-MWI-13B-X, 1516-MW Date of Decision Letter: 10 September 2019 Date of the Partnership Framework Agreement: 29 Programme title: New Vaccine Support (NVS), Rotavirus, Rotavirus Requested product presentation and formulation of vaccine: RV1, 1 dose/plastic tube, liq Programme Duration: 2012-2020 Programme Budget (indicative): (subject to the terms of the Papplicable) 2012-2018 2019 2020 2021 Programme Budget (US\$) 17,349,048 3,415,500 3,199,500 -	Vaccine grant number: 1214-MWI-13B-X, 1516-MWI-13b-X, 1720 Date of Decision Letter: 10 September 2019 Date of the Partnership Framework Agreement: 29 October 200 Programme title: New Vaccine Support (NVS), Rotavirus, Routine Vaccine type: Rotavirus Requested product presentation and formulation of vaccine: RV1, 1 dose/plastic tube, liq Programme Duration: 2012-2020 Programme Budget (indicative): (subject to the terms of the Partnership Frapplicable) 2012-2018 2019 2020 2021 2022 Programme Budget (US\$) 17,349,048 3,415,500 3,199,500	Vaccine grant number: 1214-MWI-13B-X, 1516-MWI-13b-X, 1720-MWI-13b-X Date of Decision Letter: 10 September 2019 Date of the Partnership Framework Agreement: 29 October 2013 Programme title: New Vaccine Support (NVS), Rotavirus, Routine Vaccine type: Rotavirus Requested product presentation and formulation of vaccine: RV1, 1 dose/plastic tube, liq Programme Duration: 2012-2020 Programme Budget (indicative): (subject to the terms of the Partnership Framework Agraphicable) Programme Budget (indicative): 2019 2020 2021 2022 2023 Programme Budget (US\$) 17,349,048 3,415,500 3,199,500	

 $^{^1}$ This is the entire duration of the programme. 2 This is the total amount endorsed by Gavi for the entire duration of the programme. 3 This is the amount that Gavi has approved.



13. Procurement agency: UNICEF. The Country shall release its co-financing payments each year to

UNICEF.

14. Self-procurement: Not applicable

15. Co-financing obligations:

According to the co-financing policy, the Country falls within the group:

Initial self-financing

The following table summarises the co-financing payment(s) and quantity of supply that will be procured with such funds in the relevant year.

Type of supplies to be purchased with Country funds in each year	2019
Number of vaccine doses	139,500
Number of AD syringes	_
Number of re-constitution syringes	_
Number of safety boxes	-
Value of vaccine doses (US\$)	313,371
Total co-financing payments (US\$) (including freight)	322,500

16. Operational support for catch-up campaigns:

Not applicable

17. Additional Reporting Requirements:

	Due dates
o prepare for the annual procurement of vaccines; Country shall submit the ollowing information each year:	ami tebr
 vaccine stock levels including buffer stock, by end of March; 	31 March
 number of children to be vaccinated, wastage rates, any proposed changes in product, presentation or use, or minimum co-financing levels and vaccines received, by mid-May. 	15 May
 Countries shall report the actual switch date in the first renewal request following the actual implementation. 	



18.	Financial clarifications:
	Not applicable
19.	Other conditions:
	Not applicable

Signed by,

On behalf of Gavi

Thabani Maphosa,

Managing Director, Country Programmes

10 September 2019